Durham Drug Developer NephroGenex Files For $46 Million IPO

Published: Dec 27, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NephroGenex Inc., which is developing kidney disease treatments, filed to go public on Tuesday with the intention of raising $46 million. The Durham-based company pegged its initial public offering price at between $12 and $14 and will use the proceeds to further develop its therapeutics. Specifically, NephroGenex will continue clinical development of a drug called Pyridorin for the treatment of diabetic nephropathy in patients with Type 2 diabetes, including an anticipated Phase 3 trial.

Help employers find you! Check out all the jobs and post your resume.

Back to news